M-02 · Confidential Teaser
Active
Molecular Diagnostics Lab Platform
Multi-state · HQ North Texas
Structure
Entry guidance ~1.0× FY2025 revenue · asset sale
§ 01
Overview
- Multi-location, CLIA-certified molecular diagnostics laboratory platform operating 24/7 across two states.
- Operating since 2019; high-volume infectious disease PCR testing.
- Diversified payer exposure and established regulatory infrastructure.
- Clinically essential, non-discretionary segment of healthcare diagnostics.
§ 02
Financial Highlights (FY2025)
- Revenue: $9.41 million.
- Gross profit: $5.22 million (55.5% gross margin).
- 73% year-over-year revenue growth.
- Approximately 3,800 PCR samples per month.
- ~$2.49 million in owned laboratory equipment; no material equipment debt.
§ 03
Strategic Positioning
- Processing significantly higher PCR volumes than comparable independent regional labs.
- Scalable infrastructure with meaningful operating leverage.
- Licensed, high-barrier laboratory platform; multi-state licensure reduces replication risk.
- Clear pathway to a 6,000+ samples-per-month target.
- Margin expansion potential through procurement optimization and AR tightening.
- Positioned for strategic tuck-in or platform expansion.
CONFIDENTIAL · This teaser is anonymized by design. Identifying detail, the full
financial package, and current process phase are released under signed NDA to qualified
buyers. All mandates are offered as asset sales. Nothing on this page is an offer to sell
securities.
Request the full package.
Serious buyers only. The desk reads every note and responds with an
NDA and next steps. Reference M-02 is attached to this inquiry automatically.
Desk line 972-839-6333 · Mon–Fri 08:30–18:00 CT · all inquiries go through the form below